Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Endo Says It Will Cut 15% of Workforce, Reduce Forecast

June 5 (Bloomberg) -- Endo Health Solutions Inc., the maker of the painkillers Percocet and Lidoderm, reduced its profit and revenue forecasts for 2013 while saying it will cut 15 percent of its global workforce.

Endo also will explore strategic alternatives for its HealthTronics business, which provides urological services and products, and its branded drug discovery platform, the Chadds Ford, Pennsylvania-based company said today in a statement. The job cuts and other reductions in expenses may save $325 million through the middle of 2014, the company said.

The U.S. Food and Drug Administration decided May 10 that generic copies of Endo’s Opana ER may remain on the market without abuse-deterrent technology. The competition may reduce sales by as much as $120 million and cut profit by 55 cents a share, Endo said then.

“We believe these actions will leave Endo with the right cost structure, leadership and execution capabilities to drive sustainable cash flow and earnings growth over time, Rajiv De Silva, Endo’s chief executive officer, said today in the statement. 

Endo reduced its 2013 revenue forecast to $2.65 billion to $2.8 billion from $2.8 billion to $2.95 billion and cut its projected profit excluding some items to $4.10 to $4.40 a share from $4.40 to $4.70.

To contact the reporter on this story: Andrew Pollack in San Francisco at apollack1@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.